Why the study?
Does treatment with growth hormone or insulin-like growth factor-I alter serum lipoprotein(a) and LDL cholesterol levels in male patients with idiopathic osteoporosis?
Does treatment with growth hormone or insulin-like growth factor-I alter serum lipoprotein(a) and LDL cholesterol levels in male patients with idiopathic osteoporosis?
Growth hormone and insulin-like growth factor-I have divergent effects on lipoprotein metabolism, with IGF-I notably reducing lipoprotein(a) levels.
Answers are grounded in this paper and cite their sources.
GH requires Lp(a) monitoring in osteoporotic men; extends evidence of divergent lipoprotein effects versus IGF-I.
In response to treatment with growth hormone, serum levels of lipoprotein(a) increase, while those of LDL cholesterol decrease. To establish if increased levels of insulin-like growth factor-I may be of importance for these changes, we analyzed serum lipoprotein concentrations in 11 male patients with idiopathic osteoporosis who were treated with growth hormone (2 IU.m-2.d-1) or insulin-like growth factor-I (80 micrograms.kg-1.d-1) in a randomized, double-blind, cross-over study. LDL cholesterol was reduced by 0.7 mmol/L (P < .01) during growth hormone treatment but was not affected when the same patients received insulin-like growth factor-I. In contrast, mean lipoprotein(a) levels increased from 519 to 571 mg/L (P < .03) in response to growth hormone but were reduced from 538 to 478 mg/L (P < .04) during treatment with insulin-like growth factor-I. These results indicate that growth hormone exerts its effects on lipoprotein metabolism independent of insulin-like growth factor-I. Furthermore, the results suggest that treatment with insulin-like growth factor-I may reduce lipoprotein(a) levels.
No takes yet. Share an insight, caveat, or question.
Olivecrona et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: